|
Malignant neoplasm of ovary
|
0.600 |
Biomarker
|
disease |
BEFREE |
Here we assess the expression levels of progesterone receptor (PR), estrogen receptor alpha (ER) and androgen receptor (AR) using histoscore - a nuclear scoring method incorporating both proportion of positive cells and the intensity of nuclear staining - across a cohort of 107 WT1 negative EnOCs.
|
31495455 |
2019 |
|
Malignant neoplasm of ovary
|
0.600 |
Biomarker
|
disease |
BEFREE |
PARAGON: A Phase II study of anastrozole in patients with estrogen receptor-positive recurrent/metastatic low-grade ovarian cancers and serous borderline ovarian tumors.
|
31227223 |
2019 |
|
Malignant neoplasm of ovary
|
0.600 |
Biomarker
|
disease |
BEFREE |
The present study was designed to evaluate the E2-independent effect of ERα/β on leptin-mediated cell invasion and cell proliferation in ovarian cancer.
|
31077012 |
2019 |
|
Malignant neoplasm of ovary
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
ER-beta expression is reduced in breast and ovarian cancers and requires quantitation.Herein we describe a novel approach to quantifying ERβ using older mouse ovarian surface epithelium, where ERβ is expressed at lower levels than ERα and is therefore harder to detect.
|
31041737 |
2019 |
|
Malignant neoplasm of ovary
|
0.600 |
Biomarker
|
disease |
BEFREE |
Estrogen receptor (ER) positivity and progesterone receptor (PR) positivity were significant protective factors against subsequent BC and ovarian cancer.
|
29885789 |
2018 |
|
Malignant neoplasm of ovary
|
0.600 |
Biomarker
|
disease |
BEFREE |
Finally, newly diagnosed ER+ HGSOC patients were offered a maintenance therapy with Letrozole.
|
29157627 |
2018 |
|
Malignant neoplasm of ovary
|
0.600 |
PosttranslationalModification
|
disease |
BEFREE |
Our results indicate a correlation between the presence of ESR1 methylation and a better clinical outcome in HGSC patients.
|
29807696 |
2018 |
|
Malignant neoplasm of ovary
|
0.600 |
Biomarker
|
disease |
BEFREE |
The Evolution of Estrogen Receptor Signaling in the Progression of Endometriosis to Endometriosis-Associated Ovarian Cancer.
|
30302736 |
2018 |
|
Malignant neoplasm of ovary
|
0.600 |
Biomarker
|
disease |
BEFREE |
We constructed polygenic risk scores (PRS) using BC and OC susceptibility SNPs identified through population-based GWAS: for BC (overall, estrogen receptor [ER]-positive, and ER-negative) and for OC.
|
28376175 |
2017 |
|
Malignant neoplasm of ovary
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
This study uses primary cultures of mouse ovarian surface epithelium (OSE) to demonstrate that one possible mechanism by which estrogen accelerates the initiation of ovarian cancer is by up-regulation of microRNA-378 via the ESR1 pathway to result in the down-regulation of a tumour suppressor called Disabled-2 (Dab2).
|
29196616 |
2017 |
|
Malignant neoplasm of ovary
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Expression of ER (Hazard Ratio (HR) = 0.18, 95% confidence interval 0.08-0.42, <i>p</i> = 0.0002) and of PR (HR = 0.22, 95% confidence interval 0.10-0.53, <i>p</i> = 0.0011) were significantly associated with longer ovarian cancer specific survival adjusted for age, grade, treatment center, stage, and residual disease.
|
28264438 |
2017 |
|
Malignant neoplasm of ovary
|
0.600 |
Biomarker
|
disease |
BEFREE |
Ovarian cancer is a major gynaecological cancer with different subtypes and studies have suggested that estrogen receptor (ER) or progesterone receptor (PR) positivity are associated with better clinical outcomes.
|
29137401 |
2017 |
|
Malignant neoplasm of ovary
|
0.600 |
Biomarker
|
disease |
BEFREE |
Active Estrogen Receptor-alpha Signaling in Ovarian Cancer Models and Clinical Specimens.
|
28073843 |
2017 |
|
Malignant neoplasm of ovary
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
The aim of the study was to investigate the role of sema 4D and elucidate the regulatory pattern of ERα and ERβ on sema 4D expression in ovarian cancers.
|
28225892 |
2017 |
|
Malignant neoplasm of ovary
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Differential expression of estrogen receptor subtypes and variants in ovarian cancer: effects on cell invasion, proliferation and prognosis.
|
28859612 |
2017 |
|
Malignant neoplasm of ovary
|
0.600 |
Biomarker
|
disease |
BEFREE |
Accordingly, immunohistochemical analysis of ERα-negative tissue specimens from HGSOC patients showed a significantly greater TAM infiltration in premenopausal compared to postmenopausal women.
|
26797759 |
2016 |
|
Malignant neoplasm of ovary
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Conversely, estrogen receptor signaling downregulates miR-486-5p and upregulates OLFM4 expression, slowing the development and progression of ovarian cancer.
|
26871282 |
2016 |
|
Malignant neoplasm of ovary
|
0.600 |
Biomarker
|
disease |
BEFREE |
Recurrent estrogen receptor α (ERα)-positive breast and ovarian cancers are often therapy resistant.
|
25825714 |
2015 |
|
Malignant neoplasm of ovary
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Letrozole was effective for ovarian cancers with abundant expression of ERα.
|
24410765 |
2014 |
|
Malignant neoplasm of ovary
|
0.600 |
Biomarker
|
disease |
BEFREE |
Thus, miR-206 may be a promising candidate for the endocrine therapy of ERα-positive ovarian cancer.
|
24604205 |
2014 |
|
Malignant neoplasm of ovary
|
0.600 |
PosttranslationalModification
|
disease |
BEFREE |
Previous studies have shown that ESR1 methylation influences ovarian cancer development and might thus play a role regarding prognosis of ovarian carcinoma.
|
24908329 |
2014 |
|
Malignant neoplasm of ovary
|
0.600 |
Biomarker
|
disease |
BEFREE |
Estrogen and estrogen receptor (ER)-mediated signaling pathways play important roles in the etiology and progression of human breast, endometrial, and ovarian cancers.
|
25221777 |
2014 |
|
Malignant neoplasm of ovary
|
0.600 |
Biomarker
|
disease |
BEFREE |
Expression and clinical significance of estrogen-regulated long non-coding RNAs in estrogen receptor α-positive ovarian cancer progression.
|
24481591 |
2014 |
|
Malignant neoplasm of ovary
|
0.600 |
Biomarker
|
disease |
BEFREE |
This growth promoting effect of OC cell growth was mediated by miR-26a inhibition of the posttranscription of ER-α.
|
24466274 |
2014 |
|
Malignant neoplasm of ovary
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Our results demonstrate that PES1 may play important role in the progression of ovarian cancer by inversely regulating the ERα and ERβ expression.
|
24376209 |
2013 |